SCHEMBL1336563

SCHEMBL1336563

CCCOc1cccc(-c2ccc(NC(=O)c3ccccc3C(=O)O)c(F)c2)c1

nearest known ligand 0.64

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 17/20 0.64
NR4A2 P43354 7/20 0.64
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
GAA P10253 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
NR4A1 P22736 2/20 0.52
JMJD7 P0C870 1/20 0.52
NR4A3 Q92570 1/20 0.52
NR1H4 Q96RI1 1/20 0.52
FABP1 P07148 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337478 0.95 DHODH (0.71) DHODHNR4A2NPC1RAB9ASMN1; SMN2
SCHEMBL1337458 0.92 DHODH (0.67) DHODHNR4A2GAAL3MBTL1NR4A1
SCHEMBL1337021 0.88 DHODH (0.67) DHODHNR4A2SMN1; SMN2GAAL3MBTL1
SCHEMBL1336884 0.86 DHODH (0.78) DHODHNR4A2NPC1RAB9ASMN1; SMN2
SCHEMBL1335530 0.85 FABP1 (0.57) DHODHNPC1RAB9ASMN1; SMN2GAA
SCHEMBL1336938 0.84 DHODH (0.59) DHODHNR4A2SMN1; SMN2GAAL3MBTL1
SCHEMBL1335438 0.83 DHODH (0.66) DHODHNR4A2NR1H4
SCHEMBL1337733 0.82 DHODH (0.69) DHODHNR4A2NR4A1JMJD7NR4A3
SCHEMBL1337908 0.80 DHODH (0.58) DHODHNR4A2NR4A1JMJD7NR4A3
SCHEMBL15928753 0.80 ALDH1A1 (0.58) DHODHNR4A2NPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP claimed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US claimed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US claimed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US claimed
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR DHODH 1/4885NR4A2 1697/4885NPC1 1428/4885
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR DHODH 1/4885NR4A2 1697/4885NPC1 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.